期刊文献+

艾塞那肽通过激活AMPK抑制脂肪酸诱导肝细胞脂肪沉积及炎症反应 被引量:4

Exenatide inhibits fatty acid induced hepatocyte steatosis and inflammation through activating AMPK
下载PDF
导出
摘要 目的:探讨胰高血糖素样肽-1(glucagonlike peptide-1,GLP-1)受体激动剂艾塞那肽(exenatide,EXE)对肝细胞脂肪沉积作用及机制.方法:采用棕榈酸(palmitic acid,PA)诱导HepG2细胞沉积模型,将不同剂量的EXE(25-100 nmoL/L)与PA(500μmoL/L)共同孵育24 h.采用油红O染色及细胞内甘油三酯(triglyceride,TG)含量检测观察脂肪沉积程度;实时定量PCR检测(real-time quantitative PCR,qRT-PCR)脂肪酸合酶(fatty acid synthase,FAS)以及肿瘤坏死因子-α(tumor necrosis factorα,TNF-α)、白介素-6(interleukin-6,IL-6)的表达;Western blot检测p-腺苷酸激活的蛋白激酶(AMP-activated protein kinase,AMPK)及AMPK表达.我们还采用AMPK抑制剂对调控AMPK在EXE抑制脂肪沉积及炎症反应中的作用进一步的验证.结果:PA显著升高HepG2细胞中的TG及油红O含量,增加FAS的表达,与对照组比较有统计学差异(均P<0.05).EXE能剂量依赖性抑制PA诱导的TG及油红O含量升高及FAS基因激活,与PA组比较有统计学差异(均P<0.05).PA处理组TNF-α、IL-6的表达较对照组显著升高,与对照组比较有统计学差异(均P<0.05).EXE能剂量依赖性抑制PA诱导TNF-α、IL-6的表达升高,与PA组比较有统计学差异(均P<0.05).AMPK抑制剂能显著降低EXE对AMPK的激活作用,还显著降低了EXE对PA诱导脂肪沉积及FAS激动的抑制作用,与EXE单独作用组比较有统计学差异(均P<0.05).此外,AMPK抑制剂能显著降低EXE对PA诱导TNF-α、IL-6激活的抑制作用,与EXE单独作用组比较差异有统计学意义(均P<0.05).结论:EXE可能通过激活AMPK减少脂肪酸诱导肝细胞脂肪沉积及炎症反应. AIM: To detect the effect of glucagon-like peptide-1(GLP-1) agonist exenatide(EXE)on fat deposition in liver cells and explore the underlying mechanism.METHODS: A HepG2 cell deposition model was induced with palmitic acid(PA). After cells were incubated with different doses of EXE(25-100nmoL/L) and PA(500 μmoL/L) for 24 h, fatty deposition was assessed by oil red O staining and the level of intracellular triglyceride(TG).Real-time quantitative PCR(qRT-PCR) was used to detect the expression of lipid metabolism related genes, including fatty acid synthase(FAS),tumor necrosis factor α(TNF-α), and interleukin6(IL-6). The expression of p-AMPK and AMPK protein was tested by Western blot. An AMPK inhibitor was used to explore the role of AMPK in fat deposition and inflammation.RESULTS: Compared with the control group,PA significantly elevated TG and oil red O content, as well as the expression of FAS in HepG2 cells(P 〈0.05). EXE significantly inhibited PA induced elevation of TG and oil red O content, as well as FAS gene expression in adose dependent manner(P 〈0.05). The expression of TNF-α and IL-6 significantly increased in the PA treated group(P 〈0.05). EXE significantly inhibited the expression of TNF-α and IL-6 in PA treated HepG2 cells(P 〈0.05). Co-treatment with AMPK inhibitor significantly reduced the effect of EXE on AMPK, and reduced the inhibitory effect of EXE on fatty deposition and PA induced FAS activation(P 〈0.05). AMPK inhibitor significantly diminished the inhibitory effect of EXE on TNF-α and IL-6 activation induced by PA(P〈 0.05).CONCLUSION: EXE reduces fatty acid induced fatty deposition and inflammatory response in liver cells through activation of AMPK.
出处 《世界华人消化杂志》 CAS 2016年第11期1649-1657,共9页 World Chinese Journal of Digestology
基金 福建省卫生厅青年科研课题基金资助项目,No.2013-2-87~~
关键词 艾塞那肽 脂肪沉积 炎症 腺苷酸激活的蛋白激酶 Exenatide Fatty deposition Inflammation AMP-activated protein kinase
  • 相关文献

参考文献31

  • 1Fan JG, Farrell GC. Epidemiology of non- alcoholic fatty liver disease in China. J Hepatol 2009; 50:204-210 [PMID: 19014878 DOI: 10.1016/ j.jhep.2008.10.010].
  • 2Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 2015; 4:212283 [PMID: 26213556 DOI: 10.7573/dic.212283].
  • 3Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) 2015; 23:1119-1129 [PMID: 25959380 DOI: 10.1002/oby.21107].
  • 4Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013; 123:2764-2772 [PMID: 23863634 DOI: 10.1172/JCI67227].
  • 5Lee JW, Choe SS, Jang H, Kim J, Jeong HW, Jo H, Jeong KH, Tadi S, Park MG, Kwak TH, Man Kim J, Hyun DH, Kim JB. AMPK activation with glabridin ameliorates adiposity and lipiddysregulation in obesity. J Lipid Res 2012; 53: 1277-1286 [PMID: 22493094 DOI: 10.1194/jlr. M022897].
  • 6Kumase F, Takeuchi K, Morizane Y, Suzuki J, Matsumoto H, Kataoka K, A1-Moujahed A, Maidana DE, Miller JW, Vavvas DG. AMPK- Activated Protein Kinase Suppresses Ccr2 Expression by Inhibiting the NF-gB Pathway in RAW264.7 Macrophages. PLoS One 2016; 11: e0147279 [PMID: 26799633 DOI: 10.1371/journal. pone.0147279].
  • 7范建高.非酒精性脂肪性肝病的研究现状与展望[J].临床肝胆病杂志,2015,31(7):999-1001. 被引量:47
  • 8Bar~i~ N, Leroti~ I, Smir~i~-Duvnjak L, Toma~i~ V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18:3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945].
  • 9Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19:291-302 [PMID: 19359149 DOh 10.1016/ j.numecd.2008.12.015].
  • 10Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:998-1003 [PMID: 10973319 DOI: 10.1038/79697].

二级参考文献1

共引文献46

同被引文献27

引证文献4

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部